• Press Office

    Posted in category News Release by Press Office on 17/12/2013

    ABPI response to GSK announcement regarding changes to its global sales and marketing practice

The relationship between the pharmaceutical industry and medical professionals is a very important one, especially as both medicines and their use become more complex, through trends such as personalisation.

 

The ABPI Code of Practice sets strict guidelines around the organisation of meetings with doctors or other healthcare staff, and conference travel and hospitality. This code is administered on behalf of the ABPI by the Prescription Medicines Code of Practice Authority (PMCPA). 

Responding to GSK’s announcement regarding changes to its global sales and marketing practice, ABPI Chief Executive Stephen Whitehead said:

“The pharmaceutical industry is committed to increasing the transparency of payments to medical professionals and is now moving from aggregate disclosure to full disclosure, on an individual level, of payments to medical professionals on marketing and education activities. Information on sponsorship collected during 2015 will be disclosed on individual healthcare professionals in 2016, across 33 European countries. A similar arrangement will apply to contractual agreements with consultants, with individual details again to be released in 2016. Consultants are already obliged to declare their consultancy and other commercial interests when undertaking speaking engagements and in publications.

“In June 2013 the ABPI held a joint conference with the British Medical Journal to explore the current state of continuing professional development in the UK, how it compares with other countries, and where it might be heading, with a particular emphasis on pharmaceutical industry participation. The ABPI will continue to engage with medical professionals and industry colleagues on this important issue throughout the course of next year”.

Notes to Editor

Annual expenditure on medical education across the industry in the UK is around £10m a year.

About the ABPI

The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.

Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.

The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.

Media enquiries

ABPI Press Office

Tel: +44 (0) 20 7747 1441 or +44 20 7747 1410

Mobile: +44 (0) 7808 641811 or +44 7850 312064

Email: pressoffice@abpi.org.uk

 
Print this page icon Print this page
 
Please choose the subject of your enquiry from the list below:
 
Code to enter for submitting the form
Enter the above code here:
Can't read? Try different words.